<p>SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - 获取免费报告) 在周五的期权交易活动中出现了异常的交易量。交易者购买了 21,865 份该公司的看涨期权。这比平均交易量 11,198 份看涨期权增加了约 95%。</p>
<h2>内部交易活动</h2>
<p>在其他消息中，董事 Katherine Bach Kalin 在 11 月 19 日星期三以每股平均价格 1.59 美元购买了 63,400 股公司的股票，总交易额为 100,806.00 美元。收购后，该董事直接持有 104,400 股公司的股票，价值 165,996 美元。这代表其持股增加了 154.63%。此次购买在向证券交易委员会的备案中披露，相关文件可通过此链接访问。内部人士持有 1.40% 的股票。</p>
<h2>对 SELLAS Life Sciences Group 的对冲基金看法</h2>
<p>一些对冲基金最近对其在 SLS 的持仓进行了调整。Axxcess Wealth Management LLC 在第三季度购买了 SELLAS Life Sciences Group 的新股份，价值约 26,000 美元。BNP Paribas Financial Markets 在第三季度将其在 SELLAS Life Sciences Group 的股份增加了 89.2%。BNP Paribas Financial Markets 目前持有 19,724 股公司的股票，价值 32,000 美元，此前在该期间又购买了 9,299 股。Blair William &amp; Co. IL 在第二季度购买了 SELLAS Life Sciences Group 的新股份，价值 35,000 美元。ProShare Advisors LLC 在第二季度收购了 SELLAS Life Sciences Group 的新股份，价值约 43,000 美元。最后，Sei Investments Co.在第三季度购买了 SELLAS Life Sciences Group 的新股份，价值 43,000 美元。机构投资者持有公司 17.38% 的股票。</p>
<h2>分析师评级变动</h2>
<p>另外，Weiss Ratings 在 10 月 8 日星期三的研究报告中重申了对 SELLAS Life Sciences Group 的 “卖出（d-）” 评级。一位分析师给予该股票买入评级，另一位则给予卖出评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “持有”，平均目标价格为 7.00 美元。</p>
<p><strong>阅读我们关于 SLS 的最新研究报告</strong></p>
<h2>SELLAS Life Sciences Group 股票表现</h2>
<p>NASDAQ:SLS 的股票在周五的午盘交易中上涨 0.06 美元，达到 2.40 美元。该股票的交易量为 2,337,140 股，而其平均交易量为 2,993,071 股。该股票的市值为 3.4115 亿美元，市盈率为-8.55，贝塔值为 2.51。SELLAS Life Sciences Group 的 12 个月低点为 0.85 美元，12 个月高点为 2.48 美元。该公司的 50 日移动平均价格为 1.78 美元，200 日移动平均价格为 1.77 美元。</p>
<p>SELLAS Life Sciences Group (NASDAQ:SLS - 获取免费报告) 最近在 11 月 12 日星期三发布了季度财报。该公司报告季度每股收益（EPS）为-0.06 美元，超出分析师的共识预期（-0.08 美元）0.02 美元。整体来看，卖方分析师预计 SELLAS Life Sciences Group 在本年度将发布-0.57 的每股收益。</p>
<h2>关于 SELLAS Life Sciences Group</h2>
<p>（获取免费报告）</p>
<p>SELLAS Life Sciences Group, Inc 是一家临床阶段的生物制药公司，专注于开发针对癌症的活性细胞免疫疗法。公司总部位于马萨诸塞州的沃尔瑟姆，SELLAS 专注于靶向 Wilms 肿瘤 1（WT1）抗原，这是一种在多种血液和实体肿瘤中常常过表达的蛋白质。自成立以来，公司围绕使用基于肽的疫苗建立了一个管道，旨在训练患者自身的免疫系统识别并攻击 WT1 阳性的癌细胞。</p>
<p>该公司的主要产品候选药物 galinpepimut-S (GPS) 是一种针对 WT1 的多肽疫苗。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票比 SELLAS Life Sciences Group 更好</li>
<li>国会股票交易跟踪</li>
<li>META 在科技下滑中上涨，特朗普的 AI 命令受到分析师的赞扬</li>
<li>百分比收益者告诉投资者什么，以及为什么它们并没有告诉全部故事</li>
<li>TL;DR：为什么 Reddit 是新的增长股票</li>
<li>什么是股息挑战者？</li>
<li>Rocket Lab 的急剧反弹：近期动能背后的原因</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 SELLAS Life Sciences Group 吗？</h2>
<p>在你考虑 SELLAS Life Sciences Group 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买...而 SELLAS Life Sciences Group 并不在名单上。</p>
<p>虽然 SELLAS Life Sciences Group 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>SELLAS Life Sciences Group（纳斯达克代码：SLS）经历了显著的期权交易活动，购买了 21,865 份看涨期权，较平均水平上升了 95%。该股票交易价格为 2.40 美元，上涨 0.06 美元，市值为 3.4115 亿美元。内部人士和对冲基金的活动引起了关注，分析师对该股票的评级褒贬不一。该公司专注于癌症免疫疗法</p>

<p>SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) saw unusually large options trading activity on Friday. Traders acquired 21,865 call options on the company. This is an increase of approximately 95% compared to the average volume of 11,198 call options.</p>
<div class="lb-trans"><p>SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - 获取免费报告) 在周五的期权交易活动中出现了异常的交易量。交易者购买了 21,865 份该公司的看涨期权。这比平均交易量 11,198 份看涨期权增加了约 95%。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部交易活动</h2>
</div><p>In other news, Director Katherine Bach Kalin acquired 63,400 shares of the business's stock in a transaction on Wednesday, November 19th. The shares were purchased at an average price of $1.59 per share, for a total transaction of $100,806.00. Following the acquisition, the director directly owned 104,400 shares of the company's stock, valued at $165,996. This represents a 154.63% increase in their position. The purchase was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this link. 1.40% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他消息中，董事 Katherine Bach Kalin 在 11 月 19 日星期三以每股平均价格 1.59 美元购买了 63,400 股公司的股票，总交易额为 100,806.00 美元。收购后，该董事直接持有 104,400 股公司的股票，价值 165,996 美元。这代表其持股增加了 154.63%。此次购买在向证券交易委员会的备案中披露，相关文件可通过此链接访问。内部人士持有 1.40% 的股票。</p>
</div><h2>Hedge Funds Weigh In On SELLAS Life Sciences Group</h2>
<div class="lb-trans"><h2>对 SELLAS Life Sciences Group 的对冲基金看法</h2>
</div><p>A number of hedge funds have recently made changes to their positions in SLS. Axxcess Wealth Management LLC purchased a new position in shares of SELLAS Life Sciences Group during the third quarter worth approximately $26,000. BNP Paribas Financial Markets increased its stake in shares of SELLAS Life Sciences Group by 89.2% during the third quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company's stock worth $32,000 after buying an additional 9,299 shares during the period. Blair William &amp; Co. IL purchased a new stake in SELLAS Life Sciences Group in the 2nd quarter valued at $35,000. ProShare Advisors LLC acquired a new position in SELLAS Life Sciences Group in the 2nd quarter valued at about $43,000. Finally, Sei Investments Co. purchased a new position in SELLAS Life Sciences Group in the 3rd quarter valued at $43,000. Institutional investors own 17.38% of the company's stock.</p>
<div class="lb-trans"><p>一些对冲基金最近对其在 SLS 的持仓进行了调整。Axxcess Wealth Management LLC 在第三季度购买了 SELLAS Life Sciences Group 的新股份，价值约 26,000 美元。BNP Paribas Financial Markets 在第三季度将其在 SELLAS Life Sciences Group 的股份增加了 89.2%。BNP Paribas Financial Markets 目前持有 19,724 股公司的股票，价值 32,000 美元，此前在该期间又购买了 9,299 股。Blair William &amp; Co. IL 在第二季度购买了 SELLAS Life Sciences Group 的新股份，价值 35,000 美元。ProShare Advisors LLC 在第二季度收购了 SELLAS Life Sciences Group 的新股份，价值约 43,000 美元。最后，Sei Investments Co.在第三季度购买了 SELLAS Life Sciences Group 的新股份，价值 43,000 美元。机构投资者持有公司 17.38% 的股票。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Separately, Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of SELLAS Life Sciences Group in a research note on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of &#34;Hold&#34; and an average price target of $7.00.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 10 月 8 日星期三的研究报告中重申了对 SELLAS Life Sciences Group 的 “卖出（d-）” 评级。一位分析师给予该股票买入评级，另一位则给予卖出评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “持有”，平均目标价格为 7.00 美元。</p>
</div><p><strong>Read Our Latest Research Report on SLS</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 SLS 的最新研究报告</strong></p>
</div><h2>SELLAS Life Sciences Group Stock Performance</h2>
<div class="lb-trans"><h2>SELLAS Life Sciences Group 股票表现</h2>
</div><p>Shares of NASDAQ:SLS traded up $0.06 during midday trading on Friday, hitting $2.40. 2,337,140 shares of the stock were exchanged, compared to its average volume of 2,993,071. The stock has a market capitalization of $341.15 million, a price-to-earnings ratio of -8.55 and a beta of 2.51. SELLAS Life Sciences Group has a 12 month low of $0.85 and a 12 month high of $2.48. The business's 50-day moving average price is $1.78 and its 200 day moving average price is $1.77.</p>
<div class="lb-trans"><p>NASDAQ:SLS 的股票在周五的午盘交易中上涨 0.06 美元，达到 2.40 美元。该股票的交易量为 2,337,140 股，而其平均交易量为 2,993,071 股。该股票的市值为 3.4115 亿美元，市盈率为-8.55，贝塔值为 2.51。SELLAS Life Sciences Group 的 12 个月低点为 0.85 美元，12 个月高点为 2.48 美元。该公司的 50 日移动平均价格为 1.78 美元，200 日移动平均价格为 1.77 美元。</p>
</div><p>SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.08) by $0.02. As a group, sell-side analysts expect that SELLAS Life Sciences Group will post -0.57 EPS for the current year.</p>
<div class="lb-trans"><p>SELLAS Life Sciences Group (NASDAQ:SLS - 获取免费报告) 最近在 11 月 12 日星期三发布了季度财报。该公司报告季度每股收益（EPS）为-0.06 美元，超出分析师的共识预期（-0.08 美元）0.02 美元。整体来看，卖方分析师预计 SELLAS Life Sciences Group 在本年度将发布-0.57 的每股收益。</p>
</div><h2>About SELLAS Life Sciences Group</h2>
<div class="lb-trans"><h2>关于 SELLAS Life Sciences Group</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms' tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient's own immune system to recognize and attack WT1-positive cancer cells.</p>
<div class="lb-trans"><p>SELLAS Life Sciences Group, Inc 是一家临床阶段的生物制药公司，专注于开发针对癌症的活性细胞免疫疗法。公司总部位于马萨诸塞州的沃尔瑟姆，SELLAS 专注于靶向 Wilms 肿瘤 1（WT1）抗原，这是一种在多种血液和实体肿瘤中常常过表达的蛋白质。自成立以来，公司围绕使用基于肽的疫苗建立了一个管道，旨在训练患者自身的免疫系统识别并攻击 WT1 阳性的癌细胞。</p>
</div><p>The company's lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.</p>
<div class="lb-trans"><p>该公司的主要产品候选药物 galinpepimut-S (GPS) 是一种针对 WT1 的多肽疫苗。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than SELLAS Life Sciences Group</li>
<li>Following Congress Stock Trades</li>
<li>META Rises Amid Tech Decline, Trump's AI Order Praised By Analyst</li>
<li>What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story</li>
<li>TL;DR: Why Reddit is the New Growth Stock to Beat</li>
<li>What Are Dividend Challengers?</li>
<li>Rocket Lab's Sharp Rebound: What's Behind the Recent Momentum</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 SELLAS Life Sciences Group 更好</li>
<li>国会股票交易跟踪</li>
<li>META 在科技下滑中上涨，特朗普的 AI 命令受到分析师的赞扬</li>
<li>百分比收益者告诉投资者什么，以及为什么它们并没有告诉全部故事</li>
<li>TL;DR：为什么 Reddit 是新的增长股票</li>
<li>什么是股息挑战者？</li>
<li>Rocket Lab 的急剧反弹：近期动能背后的原因</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in SELLAS Life Sciences Group Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 SELLAS Life Sciences Group 吗？</h2>
</div><p>Before you consider SELLAS Life Sciences Group, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 SELLAS Life Sciences Group 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SELLAS Life Sciences Group wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买...而 SELLAS Life Sciences Group 并不在名单上。</p>
</div><p>While SELLAS Life Sciences Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 SELLAS Life Sciences Group 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Sellas Life Sciences Group 观察到异常高的期权交易量（NASDAQ:SLS）